Blog

The European healthcare technology M&amp;A landscape is undergoing a structural realignment. As bulge bracket institutions concentrate on billion-euro mega deals and generalist mid market banks struggle to price clinical assets with technology frameworks, a distinct gap has opened in the lower to mid market, the segment where the majority of Europe's HealthTech and MedTech companies actually live. Nelson Advisors is emerging as the specialist investment banking partner purpose built for exactly this segment. &nbsp;&nbsp; The Underserved Heart of European HealthTech &nbsp;&nbsp; Europe's lower to mid market healthcare technology segment is typically defined by annual revenues of €5M to €50M, enterprise values of €25M to €25M, operating EBITDA of €1M to €10M and headcounts of 20 to 250 staff. These are overwhelmingly founder-led or family-owned businesses: clinically credible, commercially proven, but usually without internal corporate development teams to run a competitive, well-structured transaction process. &nbsp;&nbsp; This is where the advisory gap is widest. The Titans of the industry, Goldman Sachs, J.P. Morgan, Morgan Stanley are structurally oriented towards deals above $1 Billion. Mid-market connectors such as Rothschild &amp; Co, Houlihan Lokey and Jefferies operate most effectively in the $100M to $1Bn range. Below those thresholds, founders have historically been left choosing between generalist regional banks that apply generic technology valuation playbooks to clinical assets, or attempting to negotiate directly with sophisticated institutional buyers, an asymmetry that rarely ends well for the seller. &nbsp;&nbsp; Generalist advisers struggle in this segment for structural reasons. They lack the scientific credibility and regulatory fluency to defend clinical value in diligence. They cannot bridge the cultural and informational gap between technical founders and institutional acquirers. And their rigid, standardised processes sit uncomfortably with businesses whose value lies in specialised knowledge, regulatory moats and clinical validation rather than simple revenue multiples. &nbsp;&nbsp; A Market That Rewards Specialists &nbsp;&nbsp; The timing of this realignment matters. European healthcare M&amp;A is in a period of renewed momentum — European healthcare M&amp;A value surged 87% in H1 2025 to €31.8 Billion even as deal counts fell, and private equity healthcare investment in Europe continues to climb sharply. At the same time, the market has entered what Nelson Advisors has called the "Great Rationalisation": a highly disciplined, metrics-centric climate in which valuations reflect clinical utility, regulatory resilience and integration readiness rather than growth narratives alone. &nbsp;&nbsp; The result is sharp bifurcation. AI-enabled platforms with genuine clinical validation command premium multiples of 6.0x–8.0x revenue, while unprofitable, undifferentiated assets drift towards distressed processes. Average HealthTech deal sizes have risen from $13.6M in Q1 2022 to $46.6M in Q1 2026, squarely in lower to mid market territory. In this environment, the adviser's ability to position a company's regulatory assets, unit economics and clinical evidence base is not a nice-to-have; it is the difference between a premium outcome and a discounted one. &nbsp;&nbsp; Navigating that environment demands exactly the capabilities specialist boutiques are built around: fluency in EU MDR/IVDR and the EU AI Act, command of reimbursement pathways, credibility with strategic and private equity buyers, and the judgment to apply disciplined frameworks, Rule of 40 economics, compliance treated as a financial asset, to businesses that generalists systematically misprice. &nbsp;&nbsp; Why Nelson Advisors &nbsp;&nbsp; Nelson Advisors was founded by Lloyd Price and Paul Hemings to serve this segment exclusively. The firm operates solely within healthcare technology, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity and Healthcare AI, across the UK, Europe and North America. That exclusivity is the foundation of its edge: sector pattern recognition, live buyer intelligence and valuation benchmarks that generalist banks cannot replicate. &nbsp;&nbsp; The second pillar is operational credibility. Nelson Advisors is practitioner led, "HealthTech entrepreneurs advising HealthTech entrepreneurs." The founding partners have collectively built, scaled and exited four HealthTech businesses since 2012, including Lloyd Price's Zesty, acquired by Induction Healthcare Group PLC in 2020, with exits secured from North American, European and FTSE-listed acquirers. Paul Hemings brings institutional weight, having advised on more than $50 Billion of M&amp;A and $40 Billion of equity and financing transactions.&nbsp; &nbsp;&nbsp; This "Founders for Founders" model applies institutional financial engineering to the real-world, often chaotic dynamics of scaling a healthcare technology business, because the partners have lived them. &nbsp;&nbsp; The third pillar is the firm's holistic strategic framework: Build, Buy, Partner, Sell. Rather than treating a transaction as an isolated event, Nelson Advisors works with boards and founders across the full corporate development lifecycle, buy-side and sell-side advisory, corporate divestitures, roll-up strategies, tech asset sales and go-to-market and international expansion strategy — typically over focused engagements of six to nine months. &nbsp;&nbsp; The Emerging Category Leader &nbsp;&nbsp; Recent independent assessments of the European HealthTech M&amp;A boutique landscape place Nelson Advisors among the specialist boutiques operating in the $25M–$500M deal range, alongside a small group of firms distinguished by proprietary methodology and deep domain expertise.&nbsp; &nbsp;&nbsp; Within that group, Nelson Advisors' positioning as "Strategic Architects", with valuation matrices that treat regulatory compliance as a financial asset and a four-lever view of value creation spanning the AI premium, unit economics, vendor consolidation and regulatory scrutiny, reflects a firm shaping the segment's playbook rather than following it. &nbsp;&nbsp; The structural forces are all pointing one way. Bulge-bracket banks are ceding the high-growth mid-market to specialist boutiques. Deal sizes are rising into the lower to mid market's core range. Regulation is deepening the premium on domain expertise. And Europe's HealthTech market itself is projected to grow from roughly $97 Billion in 2025 to over $222 Billion by 2030. For the founder-led companies that make up the backbone of European healthcare technology, the case for a dedicated, practitioner-led, sector-exclusive investment banking partner has never been stronger. &nbsp;&nbsp; Nelson Advisors is emerging as that partner: European lower to mid market healthcare technology investment banking specialists. &nbsp;&nbsp; Nelson Advisors &gt; European MedTech and HealthTech Investment Banking &nbsp; &nbsp;Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>&nbsp; Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech &nbsp;Nelson Advisors LLP &nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&nbsp;&nbsp;<a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>&nbsp;Meet Nelson Advisors @ 2026 Events &nbsp; Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; &nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USA &nbsp; Bits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; Venture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors emerging as European Lower to Mid Market Healthcare Technology Investment Banking Specialists

Nelson Advisors has been referenced in the Journal of Medical Internet Research publication 'The Views and Experiences of Integrated Care System Commissioners About the Adoption and Implementation of Virtual Wards in England: Qualitative Exploration Study'.Source: <a href="https://www.jmir.org/2024/1/e56494">https://www.jmir.org/2024/1/e56494</a>Background: Virtual wards (VWs) are being introduced within the National Health Service (NHS) in England as a new way of delivering care to patients who would otherwise be hospitalized. Using digital technologies, patients can receive acute care, remote monitoring, and treatment in their homes. Integrated care system commissioners are employees involved in the planning of, agreeing to, and monitoring of services within NHS England and have an important role in the adoption and implementation of VWs in clinical practice.Objective: This study aims to develop an understanding of the acceptability and feasibility of adopting and implementing VWs in England from integrated care system commissioners’ perspectives, including the identification of barriers and facilitators to implementation.Methods: Qualitative semistructured interviews were conducted with 20 commissioners employed by NHS England (NHSE) in various geographic regions of England. Thematic analysis was conducted, structured using the framework approach, and informed by the Consolidated Framework for Implementation Research. The COREQ (Consolidated Criteria for Reporting Qualitative Research) guidelines were followed.Virtual wards (VWs) are models of care delivery whereby patients receive the care they need at home rather than in a hospital. This includes either preventing unplanned hospital admissions or supporting people to safely leave the hospital sooner. There is considerable overlap between VW and hospital at home (HaH) models of care, and these terms are sometimes confused or used interchangeably [4]. Frequently used definitions state that HaH services provide face-to-face care at home through community-based multidisciplinary teams [5], whereas VWs are hospital-led and managed to enable the delivery of at-home acute care, monitoring, and treatment using a variable combination of face-to-face care and remote monitoring (eg, through apps, technology platforms, and wearable devices) [6,7]. The scope of VWs as a model of care varies from models using remote monitoring technology to predominantly operate without in-person intervention (eg, telehealth hubs with remote monitoring) to models more heavily reliant on multidisciplinary teams delivering in-person care in patient homes [8]. Therefore, the latter end of this continuum of care overlaps largely with HaH models. VW or HaH models of care have been used across various countries, including the United States [9,10], Australia [11], the Netherlands [12], and Saudi Arabia [13].9. Virtual wards: why are they not widely adopted across the US healthcare industry? 2023. Healthcare Technology. [2024-06-05]. <a href="https://www.healthcare.digital/single-post/virtual-wards-why-are-they-not-widely-adopted-across-the-us-healthcare-industry" data-mce-selected="inline-boundary">https://www.healthcare.digital/single-post/virtual-wards-why-are-they-not-widely-adopted-across-the-us-healthcare-industry﻿</a>

Nelson Advisors referenced in the Journal of Medical Internet Research publication 'The Views and Experiences of Integrated Care System Commissioners About the Adoption and Implementation of Virtual Wards in England: Qualitative Exploration Study'

Nelson Advisors has been referenced in JMIR Mental Health publication 'Expected Competencies and Personal Attributes of Digital Health Navigators to Support Digital Mental Health Care: Focus Group and Interview Study With Patients and Health Care Professionals'Source: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13105428/">https://pmc.ncbi.nlm.nih.gov/articles/PMC13105428/</a>Background Digital mental health apps (DMHAs), and in particular digital therapeutics (DTx), offer promising opportunities to support mental health care. However, their effective use in outpatient settings in Germany remains limited. To overcome this gap, the role of digital health navigators (DHNs) has been introduced. DHNs are trained individuals who support patients and health care professionals in selecting, using, and integrating DMHAs into care. Despite increasing interest in this role, there is limited evidence on the competencies, knowledge, and personal attributes required for DHNs to work effectively in mental health settings. Objective The study aims to explore the expected competencies, knowledge areas, and personal attributes that DHNs need to effectively support the implementation and use of DTx in outpatient mental health care. Methods As part of the prestudy of the Digital Navigators for Acceptance and Competence Development with Mental Health Apps (DigiNavi) study, a qualitative study was conducted involving 35 participants (7 general practitioners, 8 patients in general practice, 11 outpatient psychiatrists/psychologists, and 9 patients in psychiatric outpatient clinics) from different general practices and psychiatric outpatient clinics in Germany. A total of 17 semistructured interviews and 4 focus groups were conducted to explore expectations of DHNs. Data were analyzed using qualitative content analysis.However, widespread adoption remains limited in Germany [20,21]. Several key factors contribute to this [20,22], including the fact that many health care professionals (HCPs), particularly physicians, lack sufficient knowledge and awareness of DTx, their benefits, and effective implementation strategies. Time constraints faced by HCPs also pose a challenge, limiting their capacity for patient onboarding and explaining DTx usage. The complexities of integrating DTx into existing health care workflows, alongside concerns surrounding data security and patient privacy, represent additional barriers to their widespread adoption [23]. Furthermore, low patient adherence and engagement significantly hinder the successful integration of DTx [24], as well as low digital literacy among patients and HCPs [25-27].21.The German Digital Health Act (DiGa): strategy, impact, challenges and future direction. Healthcare.digital. 2025. [30-11-2025]. <a href="https://www.healthcare.digital/single-post/the-german-digital-health-act-diga-strategy-impact-challenges-and-future-direction">https://www.healthcare.digital/single-post/the-german-digital-health-act-diga-strategy-impact-challenges-and-future-direction</a> URL. Accessed.

Nelson Advisors referenced in JMIR Mental Health publication 'Expected Competencies and Personal Attributes of Digital Health Navigators to Support Digital Mental Health Care: Focus Group and Interview Study With Patients and Health Care Professionals'

Nelson Advisors has been featured in 'Hims &amp; Hers’ USD 1.15bn Eucalyptus deal signals new era for Australia’s digital health' – Dealspeak APAC.Source: <a href="https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/">https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/</a>US telehealth giant Hims &amp; Hers’ USD 1.15bn acquisition in February of Australian digital health company Eucalyptus is expected to significantly shake up the international digital health sector. The deal, set to close in mid 2026, has certainly caused a stir in Australia, where it is by far the largest acquisition of a preventative healthcare company.Pinning down precise transaction multiples is difficult given the deal’s limited valuation disclosure. But the “up to USD 1.15bn” consideration, which was based on a run‑rate derived from January 2026 revenue, and triple‑digit, year-over-year, quarterly ARR growth through 2025, implies a mid‑ to high‑single‑digit historic revenue multiple and a sizeable payday for Eucalyptus’ founder Tim Doyle and his private equity backers.This multiple is at the upper end of prevailing sector benchmarks. Nelson Advisors’ January 2026 HealthTech valuation report puts general digital health assets at 4x-6x revenue. But the report notes that premium telehealth and AI‑enabled platforms – those showing strong growth and embedded workflows – command 6x-8x+ revenue multiples.The deal valuation will have caught the attention of other players and investors in Australia’s burgeoning preventative medicine sector, which is already well known for its strong foundation in biotech, innovative digitally-driven health and AI-powered diagnostics.Sector stakeholders will also have noted the wider implications of the Eucalyptus deal, which Nelson Advisors said has turned Hims &amp; Hers into an international “powerhouse” and “represents one of the most significant consolidations in the history of the [global] telehealth industry”.

Nelson Advisors featured in Mergermarket's Dealspeak APAC

The European HealthTech landscape this week reflects a major shift away from casual consumer "wellness" apps and a deep pivot toward clinical deep-tech, workflow automation, and massive regulatory lobbying.Here are the standout developments and funding rounds dominating the industry right now:1. The Heavyweight Funding DealsThe market is favouring high-conviction, late-stage bets alongside specialised clinical devices:Neko Health’s Massive Move: Swedish preventative health startup Neko Health (co-founded by Spotify’s Daniel Ek) secured a $700M Series C round. The company revealed it has reached 100,000 members and achieved profitability at the individual clinic level, continuing its massive expansion of AI-driven full-body scans across Europe.CurifyLabs: Finnish personalized medicine startup CurifyLabs bagged €12M in Series A funding to further automate and scale its tailored drug manufacturing technology.Respiro Diagnostics: The UK lung-health startup closed a £1M round to advance its innovative breath-based diagnostics for respiratory diseases.2. Shift to Deep-Tech &amp; Cross-Border Data InteroperabilityEuropean venture capital and government backing are aggressively targeting core clinical issues:Azalea Vision Eyes Clinical Trials: Belgian healthtech firm Azalea Vision secured up to €7.5 million in EIC (European Innovation Council) Accelerator funding. The capital is designated to move their medical-grade smart contact lens, which functions as a non-invasive biosensing platform to track biomarkers via tears, into formal clinical trials.Dismantling Regional Data Silos: The EIC announced the first three winners of its health data interoperability initiative, deploying €3.78 million. Moving past small-scale pilots, projects like CARDIO-HUB (elderly remote heart monitoring) are being fully deployed to allow seamless cross-border medical data sharing.3. Regulatory Frictions: The "MDR vs. AI Act" ClashStartups and regulatory bodies are tackling the administrative bottlenecks of dual compliance:The Overlap Lobby: European healthtech developers are experiencing massive friction navigating the simultaneous compliance demands of the EU AI Act and the stringent Medical Device Regulations (MDR).Industry groups are actively lobbying the European Commission to streamline these overlapping boundaries, with EU Parliament projections estimating that harmonisation could save the ecosystem up to €3.3 billion annually in administrative bloat.The UK's Fast-Track Pivot: Seizing on the mainland's regulatory logjam, the UK's MHRA has progressed its draft Medical Devices Regulations. This establishes an "International Reliance" pathway, allowing tech manufacturers with existing approvals from trusted global regulators to bypass standard British red tape and fast-track into the UK healthcare market.4. Clinician Burnout Is Driving Software AdoptionAccording to recent data from the Philips Future Health Index, roughly 65% of European clinicians have actively ramped up their daily use of AI medical tech. Because healthcare workers are desperate to claw back time from administrative tasks, VC funding is highly concentrated on operational "plumbing", such as AI surgical infrastructure, automated clinical documentation, and scheduling platforms—rather than patient-facing apps.&gt;&gt;&gt;&gt;The European MedTech and medical device landscape is undergoing a massive, structural recalibration. The speculative "wellness app" era has completely evaporated, replaced by a heavy focus on clinical deep-tech, major regulatory overhauls, and structural legal changes.The major shifts and updates defining European MedTech include:1. The Legal Reality: The "AI Act Omnibus" &amp; MDR CollisionThe biggest structural news for device manufacturers centres on a massive breakthrough regarding how medical AI will be governed in Europe.No Duplicate Audits: Following fierce lobbying from industry group MedTech Europe over the "double-regulation" nightmare, EU co-legislators have finalised the "AI Act Omnibus" framework. It dramatically reduces duplication, meaning AI-driven medical devices will not have to undergo two completely separate compliance pathways under both the AI Act and the Medical Device Regulation (MDR/IVDR). Instead, the AI Act's high-risk safety, data quality, and cybersecurity requirements will be integrated directly into the existing MDR/IVDR framework.August 2028 Extension: Manufacturers of high-risk AI medical devices have officially been granted a major breathing-room extension to August 2028 to fully comply with high-risk obligations.The Immediate August Catch: Do not wait on everything, though. Basic transparency rules—such as explicit disclosures for patient-facing AI chatbots and clear labeling of synthetic/AI-generated healthcare content, kick in next month (August 2026).2. EU Pushes Back on Notified Bodies with Strict TimelinesIn an effort to stop innovative medical devices from fleeing Europe for the US market due to approval bottlenecks, the European Commission has introduced aggressive new rules targeting Notified Bodies.Implementing Regulation (EU) 2026/977 establishes uniform, capped maximum timelines for conformity assessments. For example, Notified Bodies are now bound to stricter time limits (e.g., 30 days for application reviews, 120 days for Quality Management System audits).They must also provide fully standardised, transparent pricing quotes to manufacturers and publish their cost structures and processing duration data annually to prevent price gouging.3. Mandatory EUDAMED Data &amp; The Next Compliance WaveThe transition period for the first four fully functional modules of EUDAMED (the EU's centralised medical device database) ended recently.All manufacturers, importers, and notified bodies are now under mandatory transparency compliance for devices entering the market.New Portal Update: The European Commission announced that the playground environment for uploading crucial Summary of Safety and Clinical Performance (SSCP) data goes live this month (July 2026), ahead of the mandatory production deadline.4. The UK's Fast-Track "International Reliance" PathwayCapitalising on mainland Europe's historical regulatory friction, the UK's MHRA has progressed its draft Medical Devices Regulations. This explicitly establishes an "International Reliance" pathway. It allows hardware and Software-as-a-Medical-Device (SaMD) manufacturers who already hold approvals from trusted global bodies (like the US FDA) to bypass British red tape and fast-track directly into the UK market.5. Late-Stage Capital &amp; Deep-Tech FundingWhile early-stage seed funding remains highly selective, capital is concentrating heavily on late-stage category leaders and deep-tech clinical hardware:Alan’s Landmark Round: The French digital health and preventative insurance platform locked in a massive €480 million Series G round at a €5.5 billion valuation, making it Europe's most valuable private HealthTech entity.Clinical Smart Lenses: Belgian MedTech firm Azalea Vision secured €7.5 million via the European Innovation Council (EIC) Accelerator. The capital will fund clinical trials for their medical-grade smart contact lens, which treats complex corneal properties and acts as a non-invasive biosensor analyzing biomarkers directly via patient tears.Interoperability Infrastructure: Moving away from small regional "pilots," the EIC deployed millions to scale cross-border clinical data infrastructure, focusing heavily on connected hardware like CARDIO-HUB (remote cardiac monitoring for the elderly). The Big Takeaway: Europe is actively rewriting its MedTech playbook. The extension of the AI Act deadlines coupled with strict new efficiency rules on Notified Bodies shows Brussels is finally listening to warnings about losing its innovation edge to the US and Asia.Nelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTlloyd@nelsonadvisors.co.ukpaul@nelsonadvisors.co.ukMeet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

This Week in European MedTech and HealthTech: 17th July 2026

The European healthcare technology and medical technology sectors have reached a major structural inflection point, transitioning from an era of venture subsidised experimentation into a phase of disciplined industrial maturity. This shift, historically characterised as the "Great Rationalisation," represents the end of the liquidity-fuelled, growth-at-all-costs environment that peaked in the early 2020s. The modern market is defined by a rigorous "flight to quality," where enterprise valuations are no longer driven by raw revenue expansion but by clinical utility, regulatory resilience, and technological defensibility. &nbsp;&nbsp; The macro capital movements within the European landscape demonstrate this selective recovery. While early-stage deal counts have contracted, capital concentration has intensified within a narrow band of validated category leaders. European digital health venture funding in the first quarter of 2026 reached approximately $1.2 Billion across 67 deals, representing a decline of 44% in capital deployed and 46% in deal count compared to the same period in 2025. However, the average deal size rose by 8% year-on-year to $21 Million, driven by late-stage mega-rounds. These transactions were led by Oviva’s $235 Million Series D, Alan’s $116 Million Series G, and DentalMonitoring’s $100 Million Series D. &nbsp; Underneath these subdued private financing volumes sits a structurally expanding end-market. The European digital health market generated an estimated $130 Billion in revenue in 2025 and is projected to compound at a 10% compound annual growth rate (CAGR) toward $314 Billion by 2034.&nbsp; &nbsp;&nbsp; Concurrently, the European HealthTech market is forecast to grow at an 18% CAGR from $97 Billion in 2025 to $222 Billion by 2030. This gap between private funding constraints and robust underlying clinical demand is the precise condition under which corporate strategics and private equity sponsors are executing consolidation plays.The Translation Gap and the Anatomy of the Founder Banker The genesis of the founder-led advisory movement lies in a fundamental inefficiency within the traditional investment banking model, often referred to as the "Translation Gap". Historically, healthcare banking and technology banking operated as distinct, hermetically sealed silos. Healthcare bankers were trained to evaluate clinical trial phases, patient registries and the slow, capital-intensive paths to regulatory clearance, but they frequently struggled with the unit economics of software scalability.&nbsp; Conversely, technology bankers evaluated assets through generalist software-as-a-service (SaaS) metrics, such as Customer Acquisition Cost (CAC), Lifetime Value (LTV), and monthly active user engagement, while remaining blind to the friction of hospital procurement, legacy Electronic Patient Record (EPR) integrations, and clinical safety standards. &nbsp;&nbsp; This Translation Gap has become a significant liability as healthcare assets have grown in technological and clinical complexity. The clinical software, surgical robotics and interoperable data stacks of the modern market exceed the analytical capabilities of generalist finance.&nbsp; To bridge this linguistic and valuation mismatch, the "Founder Banker" has emerged as a critical class of advisor. These individuals are former entrepreneurs or clinicians who have personally built, scaled, and exited healthcare technology ventures. &nbsp;&nbsp; The primary value proposition of the founder banker is rooted in operational empathy and technical fluency. Having experienced the operational friction of medical device audits, clinical trials, and NHS procurement, they can translate early-stage consumer engagement metrics into the clinical validation required by risk-averse institutional buyers. This operational pedigree allows them to de-risk complex technical assets for private equity sponsors and corporate development teams, transforming administrative hurdles into clear valuation drivers. To maintain structural clarity, market analysts must distinguish this European investment banking phenomenon from Bankers Healthcare Group (BHG). Founded in the United States in 2001 by Eric Castro, Robert Castro, and Albert Crawford, BHG is a commercial financial services firm that provides working capital, promissory notes, and point-of-sale patient lending to licensed US healthcare practitioners. Partially owned by Nashville-based Pinnacle Bank, BHG leverages a state-of-the-art loan delivery platform to manage one of the largest community bank loan networks in the United States. This practitioner-lending model is conceptually distinct from the European founder banker ecosystem, which focuses strictly on corporate finance, mid-market M&amp;A, and strategic capital raising for healthcare technology platforms.Click here to read the report in full -&nbsp;﻿<a href="https://www.healthcare.digital/single-post/the-rise-of-the-founder-banker-in-european-healthcare-technology-and-artificial-intelligence">https://www.healthcare.digital/single-post/the-rise-of-the-founder-banker-in-european-healthcare-technology-and-artificial-intelligence</a>

Nelson Advisors

Blog

Nelson Advisors emerging as European Lower to Mid Market ...

Nelson Advisors referenced in the Journal of Medical Inte...

Nelson Advisors referenced in JMIR Mental Health publicat...

Nelson Advisors featured in Mergermarket's Dealspeak APAC

This Week in European MedTech and HealthTech: 17th July 2026

The Rise of the Founder Banker in European Healthcare Tec...